Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8201275 | 0.90 | SMN1; SMN2 (0.36) | ALDH1A1SMN1; SMN2ZDHHC7TSHRMME | |
| SCHEMBL13941536 | 0.86 | MME (0.38) | ALDH1A1SMN1; SMN2ZDHHC7MMEKMT2A | |
| SCHEMBL4144659 | 0.83 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2TSHRMMEKMT2A | |
| SCHEMBL11292145 | 0.80 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2ZDHHC7TSHRMME | |
| SCHEMBL25457592 | 0.79 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2ZDHHC7TSHRMME | |
| SCHEMBL9346762 | 0.77 | KMT2A (0.36) | ALDH1A1SMN1; SMN2TSHRMMEKMT2A | |
| SCHEMBL446634 | 0.77 | MGAM (0.42) | ALDH1A1SMN1; SMN2TSHRMMEKMT2A | |
| SCHEMBL222338 | 0.76 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2ZDHHC7TSHRMME | |
| SCHEMBL2230171 | 0.76 | SMN1; SMN2 (0.32) | ALDH1A1SMN1; SMN2MMEKMT2A | |
| SCHEMBL13643069 | 0.75 | ESRRB (0.37) | ALDH1A1SMN1; SMN2ZDHHC7TSHRMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES (US) | 2014-12-25 | — | — | US | disclosed |
| US-8829052-B2 | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8808742-B2 | Compositions and methods for preparing and using same | ARDEA BIOSCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8648116-B2 | Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same | ARDEA BIOSCIENCES, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20120022076-A1 | DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES AS INHIBITORS OF MEK | MADERNA ANDREAS (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | ARDEA BIOSCIENCES, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | ARDEA BIOSCIENCES, INC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022076-A1 | DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | ALDH1A1 1961/4885SMN1; SMN2 2968/4885ZDHHC7 1825/4885 |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | ALDH1A1 1961/4885SMN1; SMN2 2968/4885ZDHHC7 1825/4885 |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | ALDH1A1 1961/4885SMN1; SMN2 2968/4885ZDHHC7 1825/4885 |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | NRAS, BRAF, MAP3K2 | ALDH1A1 2783/4885SMN1; SMN2 3442/4885ZDHHC7 3626/4885 |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | HMGCR, PCSK9, C5 | ALDH1A1 2451/4885SMN1; SMN2 101/4885ZDHHC7 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.